Jaki, Thomas, Pallmann, Philip ![]() ![]() |
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (334kB) | Preview |
Abstract
In the early stages of drug development there is often uncertainty about the most promising among a set of different treatments, different doses of the same treatment, or combinations of treatments. Multi-arm multi-stage (MAMS) clinical studies provide an efficient solution to determine which intervention is most promising. In this paper we discuss the R package MAMS that allows designing such studies within the group-sequential framework. The package implements MAMS studies with normal, binary, ordinal, or time-to-event endpoints in which either the single best treatment or all promising treatments are continued at the interim analyses. Additionally unexpected design modifications can be accounted for via the use of the conditional error approach. We provide illustrative examples of the use of the package based on real trial designs.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine |
Publisher: | University of California, Los Angeles |
ISSN: | 1548-7660 |
Date of First Compliant Deposit: | 22 March 2018 |
Date of Acceptance: | 26 September 2017 |
Last Modified: | 05 May 2023 12:53 |
URI: | https://orca.cardiff.ac.uk/id/eprint/110115 |
Citation Data
Cited 8 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |